| Model/Assay |
Assay
System |
Disease
area |
Quantity
Required |
Scientist(s)
involved |
| Sander-Cramer assay for evaluation
of spermicidal activity |
In vitro |
Contraception |
20 mg |
Dr. G. Gupta |
| Assay for vaginal contraception
in Rabbit |
In vivo |
Contraception |
This will depend on the in vitro
spermicidal conc. |
Dr. G. Gupta |
| Evaluation of Anti-proliferative
activity against human BPH-stromal
primary cells |
In vitro |
Benign Prostatic Hyperplasia |
50 mg (pure compounds) |
Dr. G. Gupta |
| In vivo assay for anti-BPH activity
in rat model |
In vivo |
Benign Prostatic Hyperplasia |
1.00 gram |
Dr. G. Gupta |
| Anti-spermatogenic activity
in rats |
In vivo |
Contraception |
3.0 grams |
Dr. G. Gupta |
| Wound healing assay |
In vitro |
Cancer |
20 mg |
Drs.
S.Musthapa, R.
Konwar,
D.P. Mishra. |
| Migration and invasion assays |
In vitro |
Cancer |
20 mg |
Dr s.
S.Musthapa, D.P.
Mishra |
| DMBA-induced mammary tumor model |
In vivo |
Breast cancer |
500 mg |
Dr. R. Konwar |
| Topoisomerase inhibition assay |
In vitro |
Cancer |
20 mg |
Dr. R. Konwar |
| Anti-proliferation Assay in Primary
cell lines |
In vitro screening for the compounds
anti-proliferation activity |
Cancer |
20 mg |
Drs.
S.Musthapa, R.
Konwar,
D.P.
Mishra |
Apoptosis assay in primary cells/
tumors
-To evaluate the anti-cancerous properties
of a particular compound using apoptosis
assay |
In vitro/ In vivo |
Cancer |
30 mg/ 500 mg |
Drs.
S.Musthapa, D.P.
Mishra |
DNMT, HDAC, HAT activity assays
- Epigenetic assays for aging and
anti-cancer research.
Assays being used to evaluate the
epigenetic targets of novel compounds
in mammalian cell lines. The major
epigenetic targets are DNMTs, HATs
and HDACs. |
In vitro |
Cancer, Aging |
30 mg |
Dr. S.
Musthapa |
| Telomerase assay |
In vitro |
Cancer, Aging |
30 mg |
Dr. S.
Musthapa |
| Chromatin Immuno Precipitation (ChIP)
assay- For DNA-protein interaction
studies |
In vitro |
Cancer / Male Reproduction/Neurobiology |
30 mg |
Dr. D. P.
Mishra |
Comet Assay
-For DNA damage |
In vitro |
Cancer, Male reproduction |
20 mg |
Drs. D.P.
Mishra,
S.Musthapa |
| Transcription assay |
In vitro |
Cancer, Male reproduction |
20 mg |
Dr. D. P.
Mishra |
| Clonogenic assay |
In vitro |
Cancer |
20 mg |
Drs.
S. Musthapa,
D.P.
Mishra |
| Proteasome inhibition assay –For
screening of proteasome inhibitors |
In vitro |
Cancer / Male Reproduction |
20 mg |
Dr. D. P.
Mishra |
| Mammalian two hybrid assay- Cellular
function |
In vitro |
Cancer / Male Reproduction |
20 mg |
Dr. D. P.
Mishra |
| Flowcytometric TUNEL assay-DNA damage,
apoptosis |
In vitro |
Cancer / Male Reproduction |
20 mg |
Drs.
S. Musthapa,
D.P.
Mishra |
| PMN Phagocytosis assay- For
screening of Phagocytosis |
In vitro |
Cancer / Male Reproduction |
20 mg |
Dr. D. P.
Mishra |
| Flurometry based autophagy assay-
For screening of Autophagy
|
In vitro |
Cancer / Male Reproduction |
20 mg |
Dr. D. P.
Mishra |
| Middle cerebral artery occlusion-
For Screening of neuroprotective activity
|
In vitro |
Neurobiology |
20 mg |
Dr. D. P.
Mishra |
| Luciferase reporter assay- For evaluation
of Transcriptional activity |
In vitro |
Cancer / Male Reproduction/Neurobiology |
20 mg |
Dr. D. P.
Mishra |
Neonatal SD rats for calvarial osteoblast
cell isolation.
-Use for assessing alkaline phosphatase
activity as a measure of osteoblast
differentiation and alizarin staining
for osteoblast mineralization |
In vitro |
Osteoporosis/ Bone diseases |
10 mg |
Drs. N. Chattopadhyay,
D. Singh,
R.
Trivedi |
| Peak bone mass measurements- Rats
administered with compound showing
promising in vitro activity. Treatment
for one month, autopsied and bones
and serum used for evaluating bone
formation and resorption parameters. |
In vivo |
Osteoporosis/ Bone diseases |
1 gram |
Drs. N. Chattopadhyay,
D. Singh,
R.
Trivedi |
| Adult SD osteopenic rat model. -Rats
ovariectomized and left for a period
of three months to develop osteopenia.
Following this, osteopenic rats administered
compound for three months, autopsied
and bones and serum used for evaluating
bone formation and resorption parameters |
In vivo |
Osteoporosis/ Bone diseases |
5 g |
Drs. N. Chattopadhyay,
D. Singh,
R.
Trivedi |
| Adult Ovariectomized Balb/c mice
model. Mice ovariectomized and administered
compound for one month, autopsied
and bones and serum used for evaluating
bone formation and resorption parameters |
In vivo |
Osteoporosis/ Bone diseases |
100 mg |
Drs. N. Chattopadhyay,
D. Singh,
R.
Trivedi |
| Bone marrow culture from adult SD
rats-For osteogenic differentiation
|
Ex vivo |
Osteoporosis/ Bone diseases |
10 mg |
Drs. N. Chattopadhyay,
D. Singh,
R.
Trivedi |
| Bone marrow culture from female
Balb/c mice-For osteoclast differentiation |
Ex vivo |
Osteoporosis/ Bone diseases |
10 mg |
Drs. N. Chattopadhyay,
D. Singh,
R.
Trivedi |
-->
|
